SLU-PP-332 vs BAM15
Both are non-peptide preclinical compounds with distinct mechanisms: ERR agonism versus mitochondrial uncoupling.
| Attribute | SLU-PP-332 | BAM15 |
|---|---|---|
| Human evidence | No therapeutic human administration evidence identified. A 2026 human-liver S9 study addresses metabolism/detection, not clinical exposure. | No therapeutic human trial evidence was identified. |
| Research focus | Exercise-mimetic, metabolism and obesity research | Obesity, insulin resistance and metabolic research |
| Regulatory status | No FDA/EMA-approved medicine identified. | No FDA/EMA-approved medicine identified. |
| Route / formulation | This is a small molecule, not a peptide. Oral commercial capsules are not validated by preclinical papers. | This is not a peptide; commercial oral products have no established clinical validation. |
Why these are compared
These compounds appear in the experimental exercise/metabolic compounds evidence landscape, but they are not interchangeable. SLU-PP-332 is synthetic small-molecule estrogen-related receptor agonist studied in exercise-mimetic, metabolism and obesity research; BAM15 is small-molecule mitochondrial protonophore/uncoupler studied in obesity, insulin resistance and metabolic research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
SLU-PP-332: Preclinical only; no therapeutic human exposure identified.
BAM15: Preclinical only — compelling mouse metabolic data, no human therapeutic evidence.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No human head-to-head or therapeutic human evidence. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty. For any compound with little or no established human exposure, published human safety and efficacy data would also materially change the evidence picture.